Why BioMarin Pharmaceutical Inc. (BMRN) stock moved
BioMarin Pharmaceutical Inc. (BMRN) shares rose 0.8% to $59.70 as of July 22, 2026, a slight gain from the prior close of $59.21. BestStocks flagged the session as a major change for BMRN. Below, we break down what changed for BMRN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
BMRN climbed 0.8% to $59.70
BMRN rose 2.31% to $59.19 in early trading on below-average volume (0.50x typical). A Zacks Style Scores article from July 1 highlighted BMRN as a strong value stock based on its investing style framework. Monitor whether volume picks up through the session and whether the move sustains into the close; check for any concurrent earnings, pipeline, or regulatory announcements not yet reflected in the evidence.
What it means for BioMarin Pharmaceutical Inc. investors
For BioMarin Pharmaceutical Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.8% session move; Positive price momentum. Weighing against that: New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $87.40, implying +46.4% upside from $59.70. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 12 days out, the next report is the most likely near-term test of the move.
BMRN price reaction
BMRN last traded at $59.70, up $0.49 (+0.83%) from the previous close of $59.21. The session traded on 0.2× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $55.90 and $60.35, and it currently sits about 85% of the way up that band.
Bullish and bearish analyst opinions on BioMarin Pharmaceutical Inc. (BMRN)
The consensus analyst price target on BioMarin Pharmaceutical Inc. (BMRN) is $87.40, 46.4% above the recent $59.70. Over the past 90 days analysts logged 0 upgrades, 11 maintains, and 0 downgrades. Here is how the bullish and bearish cases on BMRN line up.
The bullish case
- Wall Street's consensus price target of $87.40 implies +46.4% upside from $59.70.
- The Street's most bullish target is $120.00 (+101.0%).
- Positive 0.8% session move.
- Positive price momentum.
The bearish case
- The most bearish analyst target is $50.00 (-16.2%).
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 22, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for BMRN
Frequently asked questions about BMRN
Why did BioMarin Pharmaceutical Inc. (BMRN) stock move?
BMRN rose 0.8% to $59.70. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did BMRN stock rise?
BMRN gained 0.83% ($0.49) versus the prior close of $59.21, last trading at $59.70 on 0.2× average volume.
When is BioMarin Pharmaceutical Inc.'s next earnings date?
BMRN's next earnings report is estimated for 2026-08-03 — about 12 days away.
What is the analyst price target for BMRN?
The consensus analyst price target for BMRN is $87.40, about 46.4% above the current $59.70. Over the past 90 days, analysts recorded 0 upgrades, 11 maintains, and 0 downgrades.
How BestStocks tracks BMRN
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared BMRN-specific materiality thresholds, triggering an evidence check. It draws on 3 tracked change events for BMRN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.